← Back to Search

Maestro2 OCT Screening for Glaucoma

N/A
Waitlist Available
Led By Nevin W. El-Nimri, OD, PhD
Research Sponsored by Topcon Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects 22 years of age or older on the date of data collection (retrospective) or informed consent (prospective)
Be older than 18 years old
Must not have
Concomitant diseases known to affect the visual field: history of leukemia, dementia, Parkinson's disease, Alzheimer's disease, stroke, or autoimmune diseases
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights
No Placebo-Only Group

Summary

This trial seeks to create a reliable screening process for medical conditions by gathering data from multiple sources.

Who is the study for?
This trial is for people aged 22 or older with good vision (20/40 or better in each eye) who can understand and sign the consent form. It's not suitable for those unable to undergo eye tests, with certain diseases affecting vision, a history of complex eye surgery, or poor-quality scans.
What is being tested?
The study aims to develop and validate a new screening process using Maestro2 OCT technology by collecting data from various sites across the U.S., both looking back at past cases and enrolling new participants.
What are the potential side effects?
Since this trial involves non-invasive imaging without medication or surgical intervention, there are no direct side effects associated with Maestro2 OCT. However, discomfort from bright lights during scanning may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 22 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have diseases like leukemia, dementia, or Parkinson's that affect vision.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
RNFL and GCL thickness

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Pathology (glaucoma) armExperimental Treatment1 Intervention
Group II: Normal armExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Topcon CorporationLead Sponsor
12 Previous Clinical Trials
1,679 Total Patients Enrolled
2 Trials studying Glaucoma
264 Patients Enrolled for Glaucoma
Mary Durbin, PhDStudy ChairTopcon Corporation
Nevin W. El-Nimri, OD, PhDPrincipal InvestigatorTopcon Corporation
~252 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top